Rilzabrutinib active, safe in immune thrombocytopenia
Rilzibrutinib induced rapid and durable clinical activity in previously treated patients with immune thrombocytopenia, according to results of a phase 1/phase 2 clinical trial published in The New England Journal of Medicine.Additionally, the oral Bruton tyrosine kinase inhibitor demonstrated a low-grade safety profile.
Source: healio.com